Unknown

Dataset Information

0

Recombinant mumps virus as a cancer therapeutic agent.


ABSTRACT: Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21(st) century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.

SUBMITTER: Ammayappan A 

PROVIDER: S-EPMC4980112 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recombinant mumps virus as a cancer therapeutic agent.

Ammayappan Arun A   Russell Stephen J SJ   Federspiel Mark J MJ  

Molecular therapy oncolytics 20160810


Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21(st) century, the  ...[more]

Similar Datasets

| S-EPMC4976866 | biostudies-literature
2019-02-01 | GSE125257 | GEO
2019-03-21 | GSE128625 | GEO
| PRJNA525871 | ENA
| S-EPMC6628141 | biostudies-literature
| S-EPMC7196313 | biostudies-literature
| S-EPMC112006 | biostudies-literature
| S-EPMC5234798 | biostudies-literature
| S-EPMC4753134 | biostudies-literature
| S-EPMC8790423 | biostudies-literature